


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Valbenazine. [Updated 2023 Sep 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Valbenazine

Revised: September 15, 2023.

CASRN: 1025504-45-3



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recommends that breastfeeding be avoided during valbenazine therapy and for 5 days after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Valbenazine

CAS Registry Number

1025504-45-3

Drug Class

Breast Feeding

Lactation

Milk, Human

Vesicular Monoamine Transporter 2 Inhibitor